GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Biomark Diagnostics Inc (FRA:20B) » Definitions » YoY EPS Growth

Biomark Diagnostics (FRA:20B) YoY EPS Growth : -250.00% (As of Sep. 2024)


View and export this data going back to 2014. Start your Free Trial

What is Biomark Diagnostics YoY EPS Growth?

YoY EPS Growth is the percentage change of Earnings per Share (Diluted) over the past twelve months. Biomark Diagnostics's YoY EPS Growth for the quarter that ended in Sep. 2024 was -250.00%.

Biomark Diagnostics's Earnings per Share (Diluted) for the three months ended in Sep. 2024 was €-0.01.

Biomark Diagnostics YoY EPS Growth Historical Data

The historical data trend for Biomark Diagnostics's YoY EPS Growth can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Biomark Diagnostics YoY EPS Growth Chart

Biomark Diagnostics Annual Data
Trend Mar15 Mar16 Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24
YoY EPS Growth
Get a 7-Day Free Trial Premium Member Only Premium Member Only -85.71 - -7.69 - -

Biomark Diagnostics Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
YoY EPS Growth Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 75.00 - - - -250.00

Biomark Diagnostics YoY EPS Growth Calculation

YoY EPS Growth is the percentage change of Earnings per Share (Diluted) over the past twelve months.

Biomark Diagnostics's YoY EPS Growth for the fiscal year that ended in Mar. 2024 is calculated as:

YoY EPS Growth (A: Mar. 2024 )
=(Earnings per Share (Diluted) (A: Mar. 2024 )-Earnings per Share (Diluted) (A: Mar. 2023 ))/ | Earnings per Share (Diluted) (A: Mar. 2023 ) |
=(-0.014--0.014)/ | -0.014 |
=0.00 %

Biomark Diagnostics's YoY EPS Growth for the quarter that ended in Sep. 2024 is calculated as:

YoY EPS Growth (Q: Sep. 2024 )
=(Earnings per Share (Diluted) (Q: Sep. 2024 )-Earnings per Share (Diluted) (Q: Sep. 2023 )) / | Earnings per Share (Diluted) (Q: Sep. 2023 )) |
=(-0.007--0.002)/ | -0.002 |
=-250.00 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Biomark Diagnostics YoY EPS Growth Related Terms

Thank you for viewing the detailed overview of Biomark Diagnostics's YoY EPS Growth provided by GuruFocus.com. Please click on the following links to see related term pages.

Biomark Diagnostics Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Biomark Diagnostics Inc (FRA:20B) » Definitions » YoY EPS Growth
Comparable Companies
TSXV:AVCR XCNQ:SONA TSXV:TELO XCNQ:IZO TSXV:ARC TSX:SZLS TSXV:JUMP XCNQ:VTAL NEOE:MEDV TSXV:MBI.H TMO DHR SHSE:603259 IDXX IQV A XSWX:LONN MTD ICLR ILMN
Traded in Other Exchanges
BMKDF:USA 20B:Germany BUX:Canada
Address
130 - 3851 Shell Road, Richmond, BC, CAN, V6X 2W2
Website
https://www.biomarkdiagnostics.com
Biomark Diagnostics Inc is a Canada-based oncology-focused company. It is engaged in the development of the early-stage cancer diagnostic technology platform. The company develops non-invasive cancer diagnostic solutions which will help to detect, monitor, and assess early cancer treatment. Its research and development are focused on the role that metabolomics plays in early cancer detection. The company's objective is to commercialize its inventive technology. and strive to increase the predictive accuracy in early-stage cancer detection.

Biomark Diagnostics Headlines

No Headlines